Fast Track Designation recognizes both the urgent need for new therapies in pMN and the compelling early clinical activity generated to date with budoprutug,” said Edgar Charles, M.D., Chief Medical ...

Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing ...

Budoprutug receives FDA Fast Track status for primary membranous nephropathy after phase 1b data demonstrate clinical activity and safety.

Continued FDA approval of iptacopan was contingent on 2-year trial data ...

Novartis (SWX:NOVN) reported final two year Phase III results for Fabhalta in IgA nephropathy. Data showed significant long ...

The campaign features newly published research from Board members living with IgAN, alongside new educational resources to support patients and families. Together, these efforts reflect the Foundation ...